Long-term safety of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), a novel orally administered combination endectocide for dogs

Credelio Quattro™(洛替拉纳、莫昔克汀、吡喹酮和吡喹酮咀嚼片)是一种新型口服复方犬用驱虫药,其长期安全性研究。

阅读:1

Abstract

BACKGROUND: The combination of lotilaner, moxidectin, praziquantel, and pyrantel pamoate (Credelio Quattro) is a novel systemic endectocide that provides month-long effectiveness in dogs after a single oral treatment. The safety of Credelio Quattro flavored chewable tablets was investigated when administered orally at the upper end of the recommended dosage range (20-41 mg/kg lotilaner, 0.02-0.04 mg/kg moxidectin, 5-10 mg/kg praziquantel, and 5-10 mg/kg pyrantel) and multiples thereof when administered long term. METHODS: The study was randomized and blinded, with parallel groups beginning in healthy 8-week-old Beagle dogs and continuing until they reached adulthood. A total of 32 dogs were randomized among four groups (8 dogs/group) to nontreated controls or to treated groups at target doses of 1×, 3×, or 5× the maximum dose. Treatment was administered on nine occasions to dogs in a fed state every 4 weeks, with the control group receiving placebo tablets. Assessment of safety was based on regular health observations, complete physical/neurological examinations, food consumption, clinical pathology evaluations (hematology, clinical chemistry, and urinalysis), body weight, and macroscopic and microscopic examinations of collected tissues. RESULTS: Credelio Quattro did not induce any serious treatment-related adverse effects based on health observations, physical/neurological examinations, food consumption, clinical pathology, body weight, or macroscopic and microscopic examinations. The only non-serious treatment-related effects of Credelio Quattro were a dose-dependent increase in the frequency of discolored feces, diarrhea, and vomiting (including hypersalivation associated with vomiting in two of the 5× dogs). CONCLUSIONS: This study demonstrates that Credelio Quattro exhibits a wide safety margin when administered monthly to puppies and dogs at the maximum recommended commercial dose, with only transient gastrointestinal symptoms similar to other oral antiparasitic products observed. Therefore, Credelio Quattro may be safely administered to dogs each month in accordance with the approved label.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。